GCC19CART for Patients With Metastatic Colorectal Cancer

Study ICT-GCC19CART-US-001 (CARAPIA-1) is a Phase 1 study evaluating the safety, tolerability, clinical activity, pharmacokinetics and pharmacodynamics of GCC19CART in subjects with relapsed or refractory metastatic colorectal cancer.

Trial Details

NCT ID
NCT05319314
Phase
PHASE1
Sponsor
Lyell Immunopharma, Inc.
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • GCC19CART
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • San Francisco, California, United States|37.77493,-122.41942
  • Aurora, Colorado, United States|39.72943,-104.83192
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • Adults \> 18 years old
  • Clinical and histopathological diagnosis of metastatic colorectal cancer
  • Guanylate Cyclase (GCC) positive disease as determined by immunohistochemistry (IHC). Positivity on staining of archival tumor tissue is adequate.
  • Limited liver disease (less than 7 lesions with largest lesion less than 3 cm)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →